Free tool
FAERS Monitor: Natacyn
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050514 or its brand name (Natacyn, Natamycin). Reports on generic versions are filed under their own applications.
Reports
410
Serious
307
75% of reports
Hospitalization
160
Death reported
96
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective117
- condition aggravated100
- off label use81
- somnolence64
- abdominal distension62
- abdominal pain59
- vomiting59
- appendicitis58
- appendicolith58
- ascites58
- hyponatraemia58
- nausea58
- ventricular fibrillation58
- dry mouth57
- general physical health deterioration57
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 6 |
| 2012 | 6 |
| 2013 | 7 |
| 2014 | 2 |
| 2015 | 10 |
| 2016 | 13 |
| 2017 | 15 |
| 2018 | 18 |
| 2019 | 21 |
| 2020 | 23 |
| 2021 | 47 |
| 2022 | 49 |
| 2023 | 67 |
| 2024 | 54 |
| 2025 | 43 |
| 2026 | 28 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,749 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| appendicolithSignal | 58 | 9052.7 | 6967.5 | 438,613 |
| appendicitisSignal | 58 | 320.5 | 252.3 | 18,050 |
| ventricular fibrillationSignal | 58 | 269.2 | 212.0 | 15,162 |
| ascitesSignal | 58 | 101.4 | 79.9 | 5,663 |
| hyponatraemiaSignal | 58 | 52.9 | 41.7 | 2,906 |
| dry mouthSignal | 57 | 36.1 | 28.3 | 1,914 |
| abdominal distensionSignal | 62 | 30.5 | 24.2 | 1,747 |
| general physical health deteriorationSignal | 57 | 25.3 | 19.9 | 1,312 |
| condition aggravatedSignal | 100 | 16.9 | 14.2 | 1,499 |
| somnolenceSignal | 64 | 16.3 | 13.0 | 913 |
| abdominal painSignal | 59 | 13.0 | 10.3 | 649 |
| vomitingSignal | 59 | 6.4 | 5.1 | 272 |
| off label useSignal | 81 | 4.7 | 3.9 | 246 |
| drug ineffectiveSignal | 117 | 4.6 | 3.9 | 342 |
| nauseaSignal | 58 | 3.8 | 3.0 | 119 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.